IL17A and COVID-19: There were also no significant differences in the rate of COVID-19 mortality between the patients with psoriasis receiving IL-17 inhibitors and those receiving non-biologics in the children group (RR: 38.50; 95% CI: 0.99-1496.08; P = 0.05) and the NA group (RR: 2.38; 95% CI: 0.26-22.03; P = 0.45), respectively (Figure 4C).